|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0141 - 0.0141|
|52 Week Range||0.0090 - 0.0290|
|Beta (5Y Monthly)||1.79|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.25|
Manhattan Scientifics, Inc. (OTCQB:MHTX) owns 50+ Million shares of its former wholly-owned subsidiary cancer diagnostic company Imagion Biosystems Ltd. (AX:IBX). Volume trading yesterday exceeded 80 million shares @ high of AU $0.010. Manhattan Scientifics acquired and funded 10 years early R&D of IBX now anticipating possible US FDA approval to initiated human cancer testing.
Manhattan Scientifics Inc. (MHTX: OTCQ: BB) , a principal & major shareholder of Imagion Biosystems Ltd. (IBX.AX) announces IMAGION’S initiation of manufacturing medical devices and pharma products to be used in first human clinical studies of very early cancer detection as approved by the FDA.
Manhattan Scientifics Inc. (MHTX: OTCQ: BB) announces business updates on its two nano technologies.